A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus.

Ilson, D H; Forastiere, A; Arquette, M; Costa, F; Heelan, R; Huang, Y; Kelsen, D P

Ilson, D H; Forastiere, A; Arquette, M; Costa, F; Heelan, R; Huang, Y; Kelsen, D P.

Affiliation

Ilson DH; Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

Cancer J ; 6(5): 316-23, 2000.

Article in En | MEDLINE | ID: mdl-11079171

Subject(s)

Antineoplastic Agents, Phytogenic/therapeutic use; Antineoplastic Agents/therapeutic use; Carcinoma/drug therapy; Cisplatin/therapeutic use; Esophageal Neoplasms/drug therapy; Paclitaxel/therapeutic use; Adenocarcinoma/drug therapy; Adult; Aged; Antineoplastic Agents/administration & dosage; Antineoplastic Agents/toxicity; Antineoplastic Agents, Phytogenic/administration & dosage; Antineoplastic Agents, Phytogenic/toxicity; Carcinoma, Squamous Cell/drug therapy; Cisplatin/administration & dosage; Cisplatin/toxicity; Female; Humans; Male; Middle Aged; Paclitaxel/administration & dosage; Paclitaxel/toxicity; Time Factors

Search on Google

XML

PubMed Links

Collection: 01-internacional Health context: 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Esophageal Neoplasms / Carcinoma / Cisplatin / Paclitaxel / Antineoplastic Agents / Antineoplastic Agents, Phytogenic Type of study: Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Cancer J Year: 2000 Document type: Article

Search on Google

XML

PubMed Links